(Dostarlimab)Biosimilar Reference Antibody-GS40192 新品

货号：GS40192

Dostarlimab is a fully human monoclonal antibody used as an immune checkpoint inhibitor for the treatment of cancer. Marketed under the brand name Jemperli®, it is approved for use in specific molecularly defined subsets of solid tumors. Its primary indications include mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) recurrent or advanced endometrial cancer, and dMMR/MSI-H solid tumors that have progressed following prior treatment and have no satisfactory alternative options. Dostarlimab works by blocking a key inhibitory pathway on T cells, thereby restoring anti-tumor immune responses.